"...Finally, all roads in Connecticut lead to Yale. The University engages in a boggling amount of medical research and teaching activity. Who pays for it? Here is a reported list of some of its corporate funding partners who engage in pharmaceutical-related business: Boehringer, Bristol-Myers, Roche, Merck, Ziopharm Oncology, Achillion, CuraGen Corp., Metrum Research Group and Orbi Med, a company that does asset management in the global health sciences sector and has $5 billion in assets.
A 2008 Archstone Consulting study concluded pharma companies added more than $14 billion to the Connecticut economy in that year. And Connecticut colleges and universities laid out about $600 million for bioscience research in 2008, which was 81 percent of their whole academic research-and-development pie.
Connecticut is a relatively small state. To have all these pharmaceutical titans converge on it (and especially at the States most famous institution, Yale) versus releasing one boys psychiatric-drug history (an event that could start a domino effect within the whole pharmaceutical industry), who is going to exert pressure? Who is going to play its cards? Who is going to call in favors to keep secrets?..."